# A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Study · id `cardio:ct-nct03550443` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03550443](<https://clinicaltrials.gov/study/NCT03550443>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03550443

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1323 participants.

## Technical summary

Registry record NCT03550443. Randomized; double masking; primary purpose treatment. Start 2018-05-30 (actual); primary completion 2022-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1323 participants (enrolled count; ClinicalTrials.gov record NCT03550443, source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)
- Started: 2018-05-30 (actual) (ClinicalTrials.gov record NCT03550443, source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)
- Primary completion: 2022-11-30 (actual) (ClinicalTrials.gov record NCT03550443, source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)
- Completion: 2023-07-31 (actual) (ClinicalTrials.gov record NCT03550443, source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03550443, source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03550443-2023-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Bardoxolone methyl
- Intervention (Drug): Placebo
- Lead sponsor: Kyowa Kirin Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Kyowa Kirin Co., Ltd. (`cardio:org-kyowa-kirin-co-ltd`)

## Provenance

Content hash: a5de94799edfcf13d9351501a5d22cff07c2901676ff5520dfff49daf7703858
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
